Wyeth

Genetics Institute, Inc.

Wyeth Holdings Corporation

Joseph Lawrence Wooters

Bruce Arthur Green

Robert J Zagursky

Amy Wadhams Masi

David Parrish Russell

Deb Narayan Chakravarti

Geertruida Machteld Veldman

Gray D Shaw

Lih-Ling Lin

Yongchang Qiu

Jun Kuai

Elliott Nickbarg

The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of, wherein the open reading frames encode polypeptides that are surface localized on. Thus, the invention relates toopen reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by theopen reading frames, vectors comprising open reading frame sequences and cells or animals transformed with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosinginfection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with. In particular embodiments, the immunogenic compositions are used for the treatment or prevention of systemic diseases which are induced or exacerbated by. In other embodiments, the immunogenic compositions are used for the treatment or prevention of non-systemic diseases, particularly of the otitis media, which are induced or exacerbated by

[object Object]

The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT&#x3b2;R) modulators, which activate or inhibit LT&#x3b2;R signaling. LT&#x3b2;R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT&#x3b2;R complex proteins that act as LT&#x3b2;R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT&#x3b2;R, its ligands, LIGHT and LT&#x3b2;1&#x3b1;2, or its intracellular binding partners, that function to regulate LT&#x3b2;R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT&#x3b2;R signaling is provided.

Method of identifying a modulator of a LT&#x3b2;R complex signaling pathway

Cysteine added variants ('CAVs') of interleukin-3 are provided having one or more cysteine residues substituted for selected naturally occurring amino acid residues, or inserted into the polypeptide sequence, and preferably being further modified by deletion of certain N-terminal amino acids. Such CAVs may be additionally modified by the coupling of sulfhydryl reactive compounds to the introduced cysteine residue(s) without loss of bioactivity to produce selected homogeneously modified IL-3 and improved pharmaceutical compositions containing the same.

Cysteine added variants of interleukin-3 and chemical modifications

Growing community of inventors

Brighton, MA, United States of America

Joseph Lawrence Wooters